Has the 1L SoC Truly Changed in Advanced Stage DLBCL?

SOHO Brazil 2024

A. Zelenetz

Lymphoma Hot Topics in 2024: Focus on DLBCL and cHL

Yale Cancer Center

T. Sethi

Tafasitamab + Lenalidomide vs. CIT for Transplant-Ineligible R/R DLB…

Patrizia Mondello

Managing R/R LBCL Patients Treated With Pola-R-CHP in 1L and Are CAR…

University of Colorado Cancer Center

M. Kamdar

2024 Updates on Management of DLBCL

Louisville Hematology Highlights

J. Leonard

Considering Alternatives to CAR-T in R/R DLBCL

Julio Chavez

Tafasitamab/Lenalidomide for DLBCL: Which Patients and What to Expect

Amit Mehta

Bispecifics for LBCL: Guidance for Management of Toxicities in the C…

UChicago Medicine

J. Crombie

The Next Frontier of Targeted Therapy in Lymphoma

UChicago Medicine

K. Maddocks

Current Management of DLBCL From Frontline to Relapsed Disease

Dipenkumar Modi

Debates in CLL: Measuring MRD is NOT the SOC

UChicago Medicine

J. Soumerai

Hematopathology Tumor Board: Case Studies and Diagnostic Challenges …

UChicago Medicine

G. Venkataraman, A. Perry, K. Cahill, A. Akmatbekov, L. Wu

Polatuzumab Vedotin in 1L DLBCL: Perspectives on the POLARIX Trial

Juan Pablo Alderuccio

Hematologic Malignancies Update: Treatment Strategies for AML, DLBCL…

Total Health

M. Rotta

What's Current in Immunotherapy in DLBCL and FL

Houston Methodist

A. Mehta

State of the Art and Next Questions: B-Cell Lymphoma

SOHO Highlights: State of the Art and Next Questions

L. Nastoupil

DLBCL: Treatment Options for Transplant-Ineligible Patients

Amit Mehta

Optimizing 2L DLBCL Treatment Strategies for CAR-T Ineligible Patien…

Sarah Rutherford

R/R DLBCL: Are CAR-Ts Superior to Bispecific Antibodies?

Moffitt Cancer Center

A. Lazaryan

DLBCL Case Discussion: Strategies for 3L Management

Yale Cancer Center

S. Huntington, I. Isufi